Correspondence

Intestinal permeability

Sir,—Judging from recent review articles on the subject of intestinal permeability, it seems to have become the fashion to ignore completely the original contributions made by Dr Axon and successive coworkers in Leeds. I was, therefore, not too surprised to see the recent article by Ramage and colleagues (Gut 1988; 29: 57–61) which covered very similar ground (albeit with different probe molecules) to a study on intestinal permeability changes in an experimental rat model reported some time ago.1 After all, it is always important to see confirmatory studies and there were some interesting new aspects in the recent paper. I was surprised, however, to see that Ramage and colleagues (and presumably the referees of their paper) did not think it necessary to acknowledge the existence of such a closely related study, which was one of the first to describe the use of the Nippostrongylus infected rat as an experimental model for studying passive intestinal permeability, perhaps it appeared in too obscure a journal?

In their discussion, they hint that future experiments on animal models might yield further information on the relationship between structural damage and intestinal permeability. Perhaps if they were to scan other obscure journals, they might find some help.

1 COBDEN

Preston Hospital,
North Shields,
Tyne and Wear
NE29 0LR.

References


Activity of phospholipase A2

Sir,—We read with interest the paper by Otamiri et al (Gut 1987; 28: 1445-53) concerning the activity of phospholipase A2. The authors suggest that the increase in enzyme activity may be the result of a cellular influx of calcium ions or that the ischaemia may have inactivated an endogenous phospholipase A2 inhibitor.

It has been shown in a rat model1 that platelet activation results in a profound increase in phospholipase A2 activity. Our work on experimental acute pancreatitis in the rat confirms this finding.2 The authors make no reference to the administration of anticoagulants in their experimental protocol; we therefore suggest that platelet activation may have made a significant contribution to the measured phospholipase activity.

The differences between plasma and serum phospholipase A2 activity in the rat are not seen in man. This model therefore may be of limited relevance to the clinical problems associated with intestinal ischaemia.

N C BIRD AND A J GOODMAN

Floor K,
Royal Hallamshire Hospital,
Sheffield S10 2JF.

References


Lymphokine activated killer cell activity in patients with GI cancer

Sir,—Several fundamental aspects of tumour immunology are important to the interpretation of the valuable article by J R T Monson et al (Gut 1987; 28: 1420–5) on lymphokine activated killer (LAK) cell activity in patients with gastrointestinal carcinoma.

The study confined itself to peripheral blood (PB) lymphocytes, the relevance of which has been brought into serious doubt by the work of Vose and Moore1 and Holmes, indicating that PB lymphocyte activity and type bear little similarity to the immunotumour relationship and micro-environment in vivo. It is also important to bear in mind that cytotoxic effector lymphocytes in tissues would appear to be different in number and type to those in peripheral blood.

Of the many theories thought to underlie down regulation of the immune system in carcinoma patients, that of long term specific cellular immunosuppression, relating to cancer cell minor histocompatibility antigen expression has been shown to be the case in vitro.2 This, in association with the idiotypic network concept of immune function, may be an explanation for the inability of most patients